Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Antisense
 More »

  • Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
    ISIS-SMN Rx is an antisense drug designed to alter the splicing of a closely related gene ... a deal inked in January of 2012. Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
    5-10-2013
  • BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal
    The LNA drug platform, according to Santaris, overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates ...
    4-16-2013
  • Roche and Isis Pharmaceuticals Set Sights on Huntington's
    for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with Roche's scientific knowhow in ...
    4-8-2013
  • Mystery Rare Disease Drug Earns Isis $5M from GSK
    with the specific aim of applying Isis' antisense drug discovery platform toward the ... in transthyretin amyloidosis-the first antisense drug to enter development under the ...
    2-19-2013
  • Study Details Methods for Improving Antisense Drugs
    development of improved antisense drugs by detecting and measuring their levels in cells. ... one type of antisense therapeutics, phosphorodiamidate morpholine oligomers (PMO). ...
    1-31-2013
  • Pioneering Antisense Drug Gets FDA Approval
    Crooke noted that Kynamro is the first of several systemic antisense drugs to reach the ... but requires REMS and carries boxed warning. Pioneering Antisense Drug Gets FDA Approval
    1-30-2013
  • The New Economics of Orphan Diseases
    ... At least three compounds are in Phase III trials for rare diseases. An antisense oligonucleotide targets Duchenne muscular dystrophy in collaboration with Prosensa, an ex vivo stem ...
    1-1-2013
  • Antisense Making Sense to Isis Partners
    Isis for its antisense technology. In the latest deal, AstraZeneca formed an alliance with the firm for the discovery and development of novel generation antisense therapeutics ...
    12-11-2012
  • Isis Gets More Money from Biogen Idec
    Biogen Idec and Isis Pharmaceuticals will work together to discover and develop antisense ... for the discovery of a lead antisense drug for each of the three undisclosed targets. ...
    12-10-2012
  • Novel Applications for Systems Biology
    ... Musso accomplished this in a machine-learning framework using known, published gene-phenotype associations of morpholino (antisense oligonucleotides used to inhibit specific ...
    12-1-2012
  • Pfizer Pays Isis $1.25M in Scar Treatment Deal
    The candidate, an antisense oligonucleotide, is designed to interrupt the process of fibrosis by inhibiting expression of connective tissue growth factor (CTGF). CTGF is a growth ...
    11-2-2012
  • RNAi's Enabling Powers
    ... compounds are hybrids between conventional antisense RNA molecules and RNAi compounds with the best features of both. Like antisense RNA they have good PK/PD profiles while ...
    11-1-2012
  • Advertorial: Asahi Kasei Bioprocess
    ... Synthesizing Therapeutic Oligonucleotides Nearly 250 programs are under development for therapeutics such as antisense oligos and siRNAs. Furthermore, in 2011, approximately $400 ...
    10-1-2012
  • New Target for Obesity-Related Disorders
    shown that treating obese mice with an antisense inhibitor of miR-34a corrects the ... Encouragingly, treating obese mice with an antisense inhibitor of miR-34a restored levels ...
    9-21-2012
  • Biotech Valuations at trough levels
    ... Isis (ISIS) -Isis has developed a second-generation antisense platform over many years, which has been partnered with a number of companies focused on treating cardiovascular and ...
    8-13-2012
  • More »

    Journal Articles

  • Interleukin-10 Antisense Oligodeoxynucleotide Suppresses IL-10...
    Wasin Charerntantanakul, Watchara Kasinrerk
    Viral Immunology
    Interleukin-10 Antisense Oligodeoxynucleotide Suppresses IL-10 Expression and Effects on ... In this study we evaluated the potential of phosphorothioate-modified IL-10 antisense ...
  • Long-Term Culture of Human Gingival Keratinocyte Progenitor Cells...
    Marc Kirschner, André Montazem, Hugo St. Hilaire, Aurelian Radu
    Stem Cells and Development
    Keratinocyte cultures were generated from human subjects ranging from 17 to 92 years of age and retrovirally transduced with a 14-3-3 s antisense RNA expression construct. In ...
  • Differential Regulation of the Myosin Heavy Chain Genes α and...
    Sara Danzi, Steven Klein, Irwin Klein
    Thyroid
    β in Rat Atria and Ventricles: Role of Antisense RNA Thyroid Background: The myosin heavy ... MHC genes, a and ß, and the ß-MHC antisense (AS) gene in the rat ventricles and atria. ...
  • Catechin-Vanilloid Synergies with Potential Clinical Applications...
    Dorothy M. Morré, D. James Morré
    Rejuvenation Research
    Catechin-vanilloid combinations are 10 to 100 times more effective than either catechins or vanilloids alone. Vectorforced overexpression of tNOX cDNA and antisense has ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll